Earnings History Data for ContraFect (CFRX) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
ContraFect
ContraFect Corporation is a biotechnology company. The Company is focused on protein and antibody therapeutic products for life-threatening infectious diseases. Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation is headquartered in Yonkers, New York.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14-11-2023 | AH | CFRX | ContraFect | 1.00 | -0.50 | -0.66 | 0.00 | 0.06 | 0.0 (0.00%) |
0.0 | 0.0 (0.00%) |
0.04 - 15.76 | 276,919 | 10,000 | 0 | |||
|
|
||||||||||||||||||
| 14-08-2023 | PM | CFRX | ContraFect | 2.00 | -1.94 | -1.81 | 0.00 | Contrafect GAAP EPS of -$1.94 misses by $0.13 [8/14/2023 12:49 PM] |
0.93 | -0.04 (-4.12%) |
0.0 | 0.0 (0.00%) |
0.90 - 27.44 | 54,014 | 30,000 | 0 | ||
| 31-03-2023 | PM | CFRX | ContraFect Corporation | 1.76 | -16.14 | 0.00 | -8.80 | Contrafect GAAP EPS of -$16.14 [3/31/2023 8:43 AM] |
1.84 | -0.35 (-15.98%) |
1.98 | -0.21 (-9.59%) |
1.73 - 363.20 | 129,076 | 100,000 | 5,781 | ||
| 14-11-2022 | PM | 8:30 AM ET (Nov 14) |
CFRX | ContraFect | 5.00 | -0.43 | -0.23 | 0.00 | Contrafect GAAP EPS of -$0.43 misses by $0.20 [11/14/2022 9:06 AM] |
0.1412 | 0.0 (-1.93%) |
0.15 | 0.0 (3.07%) |
0.13 - 4.54 | 308,716 | 400,000 | 2,724 | |
| 24-03-2022 | PM | 7:30 AM ET (Mar 24) |
CFRX | ContraFect | 147.00 | -0.11 | -0.24 | 0.00 | Contrafect GAAP EPS of -$0.11 beats by $0.19 [3/24/2022 9:04 AM] |
3.78 | -0.04 (-0.92%) |
3.82 | 0.01 (0.26%) |
2.11 - 4.98 | 90,649 | 96,991 | 2,201 | |
| 14-05-2021 | PM | CFRX | Contrafect Corporation | 145.00 | -0.18 | -0.26 | 0.00 | Contrafect EPS beats by $0.11 [5/14/2021 7:58 AM] |
3.85 | 0.27 (7.54%) |
3.62 | 0.04 (1.12%) |
3.44 - 8.00 | 327,701 | 410,000 | 7,313 | ||
| 30-03-2021 | PM | CFRX | ContraFect Corporation | 175.72 | -0.52 | -0.28 | 0.88 | Contrafect EPS beats by $0.08 [3/30/2021 8:56 AM] |
4.78 | 0.30 (6.70%) |
4.56 | 0.08 (1.79%) |
4.21 - 8.45 | 1,208,407 | 1,920,000 | 19,503 | ||
| 13-11-2020 | PM | CFRX | Contrafect Corporation | 152.00 | -0.19 | -0.27 | 0.00 | Contrafect EPS beats by $0.16 [11/13/2020 8:37 AM] |
5.61 | 0.34 (6.45%) |
0.0 | 0.0 (0.00%) |
2.90 - 13.40 | 94,668 | 106,218 | 0 | ||
|
|
||||||||||||||||||
| 14-08-2020 | PM | 7:30 AM ET (Aug 14) |
CFRX | ContraFect Corporation | 149.59 | -0.47 | -0.33 | -0.90 | Contrafect EPS misses by $0.55 [8/14/2020 7:40 AM] |
5.30 | 0.02 (0.38%) |
5.28 | 0.0 (0.00%) |
2.69 - 13.40 | 168,534 | 231,409 | 1,043 | |
|
|
||||||||||||||||||
| 15-05-2020 | PM | CFRX | ContraFect Corporation | 87.70 | -0.49 | -0.64 | 1.50 | Contrafect EPS beats by $0.10 [5/15/2020 7:34 AM] |
5.74 | 0.02 (0.35%) |
5.77 | 0.05 (0.87%) |
2.69 - 13.40 | 108,417 | 161,404 | 483 | ||
|
|
||||||||||||||||||